MOD-14 INDIA EXCLUSIVE
TB & Special Stains (ZN/PAS)
RNTCP / WHO TB Pathology
Sensitivity ≥91% | Specificity ≥92%
India contributes 26% of global TB burden. No other commercial platform has this. Automated AFB detection, ZN bacilli counting per field (scanty/1+/2+/3+). Direct Nikshay portal integration.
Stains: ZN, Auramine O, PAS, GMS/Methenamine Silver, Mucicarmine. Training: 85,000 ZN-stained fields + 3,000 slides.
MOD-11 INDIA EXCLUSIVE
Oral & Oropharyngeal Biopsy
WHO H&N Tumour Classification
Sensitivity ≥92% | Specificity ≥87%
India has the world's highest oral cancer burden (tobacco/betel nut). Classifies OSCC, verrucous CA, mucoepidermoid patterns adapted for South Asian oral mucosa morphology.
Types: Normal, fibrosis, OSCC low/high grade, verrucous CA, mucoepidermoid, adenoid cystic
MOD-01
Cervical Cytology (LBC)
TBS/Bethesda Classification
Sensitivity ≥95% | Specificity ≥85%
Cervical cancer is #2 cancer killer in Indian women. YOLOv9 cell detector (180K annotated cells) + EfficientNet-B5 classifier (2.1M cells). 15 cell types classified.
Types: NILM, ASC-US, ASC-H, LSIL, HSIL, SCC, AGC, AIS, Adenocarcinoma + 6 more
MOD-02
Thyroid Cytology (FNA)
Bethesda System (6 Categories)
Sensitivity ≥95% | Specificity ≥90%
High incidence in iodine-deficient Indian population. 6-category classification from non-diagnostic to malignant.
MOD-03
Urine Cytology
Paris System (TPS v2)
Sensitivity ≥95% | Specificity ≥93%
Bladder cancer rising from tobacco and industrial exposure. NHGUC, AUC, SHGUC, HGUC, LGUN classification with atypia flags.
MOD-04
Sputum & BAL Cytology
IASLC / WHO Lung
Sensitivity ≥93% | Specificity ≥88%
India has world's highest TB burden — AI TB flag is critical. Detects malignant cells, atypical squamous, adenocarcinoma clusters, small-cell clusters.
MOD-05
Pleural Fluid & Ascites
ICC Effusion Classification
Sensitivity ≥96% | Specificity ≥90%
Common in advanced cancer + TB. Classifies reactive mesothelial, mesothelioma, metastatic adenocarcinoma, lymphoma, TB clusters.
MOD-06
Gastric Biopsy (H&E)
Revised Sydney System + Vienna
Sensitivity ≥93% | Specificity ≥88%
H. pylori prevalence >60% in India. 8 lesion types including gastritis, intestinal metaplasia, dysplasia grades, and gastric carcinoma types.
MOD-07
Colorectal Biopsy
WHO GI Tumour Classification
Sensitivity ≥94% | Specificity ≥89%
Colorectal cancer rising sharply in urban India. 6 lesion types: normal, IBD, LGD, HGD, adenocarcinoma (tubular/mucinous/signet).
MOD-08
Cervical Biopsy
CIN / WHO Cervix
Sensitivity ≥95% | Specificity ≥88%
Correlates with MOD-01 for combined cervical screening pipeline — unique Prana strength. CIN1-3, HSIL, invasive SCC, adenocarcinoma.
MOD-09
Endometrial Biopsy
FIGO / WHO Endometrium
Sensitivity ≥93% | Specificity ≥87%
Endometrial cancer rising with India's obesity epidemic. Classifies atrophic, proliferative, secretory, hyperplasia, EIN/AH, endometrioid adenocarcinoma.
MOD-10
Breast Core Biopsy
B-Classification (B1-B5)
Sensitivity ≥95% | Specificity ≥91%
#1 female cancer in India. B1-B5 classification, phyllodes, lobular/ductal CA, DCIS, ER/PR/HER2 status flags. Transformative at district hospital level.
MOD-12
Immunohistochemistry (IHC)
CAP / ASCO Guidelines
Concordance >0.94 vs Expert
Replaces manual cell counting. ER, PR, HER2 (0/1+/2+/3+), Ki-67%, PD-L1 (TPS), ALK, ROS1, BRAF, MMR proteins. Enables IHC at Tier 2 hospitals.
MOD-13
Pan-Cancer Lymph Node Metastasis
AJCC Staging
Sensitivity ≥96% | Specificity ≥90%
Critical for accurate staging. Detects micro-metastasis, isolated tumour cells, macro-metastasis. A single missed LN micro-met changes the entire treatment plan.
